Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation- a single-center analysis

Ewa Marta Karakulska-Prystupiuk (ewa.prystupiuk@uckwum.pl)  
Warsaw University Hospital: Samodzielny Publiczny Centralny Szpital Kliniczny  
https://orcid.org/0000-0002-0201-5041

Jadwiga Dwilewicz-Trojaczek  
Medical University of Warsaw: Warszawski Uniwersytet Medyczny

Joanna Drozd-Sokołowska  
Medical University of Warsaw: Warszawski Uniwersytet Medyczny

Ewelina Kmín  
Warsaw University Hospital: Samodzielny Publiczny Centralny Szpital Kliniczny

Marcin Chlebus  
University of Warsaw: Uniwersytet Warszawski

Karolina Szczypińska  
Warsaw University Hospital: Samodzielny Publiczny Centralny Szpital Kliniczny

Piotr Boguradzki  
Medical University of Warsaw: Warszawski Uniwersytet Medyczny

Agnieszka Tomaszewska  
Medical University of Warsaw: Warszawski Uniwersytet Medyczny

Krzysztof Mądry  
Medical University of Warsaw: Warszawski Uniwersytet Medyczny

Jarosław Bilinski  
Medical University of Warsaw: Warszawski Uniwersytet Medyczny

Grzegorz Władysław Basak  
Medical University of Warsaw: Warszawski Uniwersytet Medyczny

Wiesław Wiktors Jędrzejczak  
Medical University of Warsaw: Warszawski Uniwersytet Medyczny

Research Article
Abstract

PURPOSE Secondary immunodeficiencies are frequently observed after allo-HSCT. This study aimed to assess the prevalence and management of hypogammaglobulinemia requiring immunoglobulin.

METHODS A retrospective single-institution study involved 126 adult patients transplanted in 2012–2019 for hematological malignancies. Patients were tested every 2–3 weeks for plasma IgG concentration during the 1st year after transplantation and supplemented with facilitated subcutaneous immunoglobulin when they met pre-defined criteria.

RESULTS The IgG concentration < 500mg/dL was diagnosed in 41 patients, while 500-700mg/dL in 25 and altogether 53 patients required IgG supplementation. The median number of IgG administrations was 2. The median time to the first IgG administration after allo-HSCT was 4.1 months, while to the next administration (if more than one was required) 53 days (prophylactic group) and 32 days (group with infections). We did not observe any significant toxicity. The 1-y overall survival in the supplemented group with infections and IgG 500-700mg/dL was significantly lower than compared to no-need immunoglobulin group (p = 0.009). The diagnosis with Acute Lymphoblastic Leukemia (ALL) or Chronic Lymphocytic Leukemia (CLL) and the use of systemic corticosteroids were associated with the average probability of hypogammaglobulinemia requiring IgG supplementation in 83.8% (versus 39.3%, p = 0.000 for other diagnosis) and 64.2% (versus 31.5%, p = 0.005 for patients without systemic corticosteroids) respectively.

CONCLUSION Over 40% of the adult recipients may require at least incidental immunoglobulin supplementation during the first year after allo-HSCT. Low IgG concentrations are associated with inferior outcomes. The subcutaneous route of IgG administration appeared to be safe and may allow for long persistence.

Introduction

Despite a considerable reduction in the incidence of non-relapse mortality following allogeneic hematopoietic stem cells transplantation (allo-HSCT) in recent years, infection-related mortality remains a challenge in the post-transplantation care [1,2]. It is related to secondary immunodeficiencies that are frequently observed and are multifactorial in etiology. According to NCCN (National Comprehensive Cancer Network) guidelines allo-HSCT recipients (with neutrophil recovery) who require intensive immunosuppressive therapy for graft-versus-host disease (GVHD) are an example of non-neutropenic patients at great risk for infections [7]. Humoral immunodeficiencies may result in a quantitative, qualitative, and functional shortage of immunoglobulins [3-6].

Immunoglobulin supplementation is commonly used in allo-HSCT recipients to prevent and treat infections, but also to modulate acute GvHD. However, there is an ongoing controversy about the benefit of such therapy, dosing regimens, and treatment monitoring of the immunoglobulin supplementation [7-11]. Additionally, immunoglobulin concentrates for subcutaneous administration are being more...
frequently administered instead of intravenous preparations, and to our best knowledge, there is no report on this subject in the available literature. Therefore, we find it important to report our experience with subcutaneous immunoglobulins.

Material And Methods

Study population

Patients treated at the Outpatient Transplantation Service, transplanted in the years 2012-2019 were included. Patients who died shortly after allo-HSCT, and had not been referred to the Outpatient Service, were not included.

Allo-HSCT

Conditioning was chosen on the discretion of treating physician and depended on the underlying hematological disease. Immunosuppressive treatment was combined of calcineurin inhibitor (cyclosporin or tacrolimus) and antiproliferative drug – either short course of methotrexate or mycophenolate mofetil. All patients with unrelated or mismatched donors received anti-T-cell globulin (2.5-5mg/kg daily) for 2-3 days in conditioning regimen. Immunosuppressive therapy was discontinued after 6-8 months following allo-HSCT if GVHD did not occur. Diagnosis and grading of acute and chronic GVHD were performed based on clinical symptoms and/or biopsies according to established criteria [6]. Grading of acute GvHD was performed according to Glucksberg score, while the severity of chronic GvHD according to National Institutes of Health (NIH) Consensus Criteria 2014 [12-14]. All patients received anti-infective prophylaxis and vaccinations according to the NIH guidelines [8,15] as described in the Supplement.

Doses and types of immunoglobulin, the indications for supplementation therapy

All patients were systematically tested (once every 2-3 weeks) and immunoglobulin concentration was determined. Serum IgG was analyzed by the immunoturbidimetric method (Roche biochemical analyzer Cobas 8000, reagent Tina-quant IgG Gen.2) at the Central Laboratory of the Medical University of Warsaw (reference normal level: 700–1600mg/L).

The patients received immunoglobulin supplementation based on the CDC (Centers for Disease Control and Prevention) recommendation and the NIH guidelines [6,8]. Due to the difficulty in accessing intravenous preparations, subcutaneous preparations were mostly used. Since the vast majority of patients had transient immunoglobulin deficiencies, IgG was administered solely if the pre-administration IgG concentration was beyond the predefined threshold.

The doses and frequencies of immunoglobulin supplementation were given according to the individual patients’ requirements. Patients with IgG level below 500mg/dL were classified as significantly deficient and received prophylactic immunoglobulins at a dose of 0.4-0.8g/kg. Patients with episodes of severe infection within first 12 months after transplantation who had IgG level below 700mg/dL received IgG supplementation at a dose of 0.5-1.0g/kg (divided into 2 doses). Preparations used were:
immunoglobulin facilitated subcutaneously by recombinant human hyaluronidase (10% infusion)-HyQvia (Baxalta Innovations GmbH, Austria) or/and solution 165mg/mL - Gammanorm (Octapharma, United Kingdom). The patients, who had received intravenous IgG (IVIg) at the beginning of the study were switched to subcutaneous preparations of immunoglobulin (after at least 28 days of the last IVIg dose). Subcutaneous preparations were always administered under the abdominal skin using a variable rate portable pump according to the producer instructions. Immunoglobulin administration was preceded by hyaluronidase administration in case of HyQvia.

Adverse events were graded according to CTCAE (Common Terminology Criteria for Adverse Events v5.0) [16].

**Statistical analysis**

This is a retrospective analysis. Medians, means and standard deviations were calculated for continuous and ordered variables. In the search of predictors that increase the need for IgG supplementation, the logistic regression model was used. The following variables were tested: gender, diagnosis being an indication for transplantation, type of conditioning, type of donor, GvHD occurrence (acute and chronic GVHD were considered only if they were documented prior to the landmark of the first IgG supplementation), age of the recipient on the day of allo-HSCT, age of the recipient at the time of diagnosis, use of corticosteroids before the first IgG supplementation. Likelihood Ratio test was calculated and presented along with standard error. If not mentioned otherwise, the level of statistical significance was set up at 5%. The analyses were conducted using R version 3.6.1. All time-to-event endpoints were computed from the day of allo-HSCT. The Kaplan-Meier estimator and log-rank test were used for overall survival.

**Results**

**Patients**

126 patients, 74(58%) males, with median age at allo-HSCT 46 years (range 18-71) were included into the analysis. For twelve patients it was the second allo-HSCT. The most prevalent diagnoses were acute leukemia, both myeloid (AML)- 54%, and lymphoblastic (ALL)- 13.5%. Baseline patients’ characteristics are shown in Table 1.

**Table 1.** Baseline patients’ characteristics (AA- aplastic anemia, AML- acute myeloid leukemia, ALL- acute lymphoblastic leukemia, GVHD- graft versus host disease, MAC- myeloablative conditioning, MDS- myelodysplastic syndrome, MPN- myeloproliferative neoplasm, MMUD- mismatched unrelated donor, MRD- matched related donor, MUD- matched unrelated donor, NMA- non-myeloablative conditioning, RIC- reduced intensity conditioning)
| Gender | Number of patients | Share of the total (%) |
|--------|--------------------|------------------------|
| Male   | 74                 | 59                     |
| Female | 52                 | 41                     |
| Age in years |                |                        |
| 18-40  | 49                 | 39                     |
| 40-60  | 55                 | 44                     |
| >=60   | 22                 | 17                     |
| Diagnosis |                   |                        |
| AML    | 68                 | 54                     |
| MDS    | 13                 | 10                     |
| ALL    | 17                 | 14                     |
| AA     | 6                  | 5                      |
| MPN    | 9                  | 7                      |
| Lymphoma | 13               | 10                     |
| Conditioning |            |                        |
| MAC    | 86                 | 68                     |
| NMA    | 5                  | 4                      |
| RIC    | 35                 | 28                     |
| Donor  |                    |                        |
| MRD    | 37                 | 30                     |
| MUD    | 66                 | 52                     |
| MMUD   | 19                 | 15                     |
| haplo  | 4                  | 3                      |
| Acute GvHD |            |                        |
| Grade 1-2 | 28            | 22                     |
| Grade 3-4 | 11            | 9                      |
| Chronic GvHD |        |                        |
| Mild   | 13                 | 10                     |
| Moderate | 46      | 37                     |
| Severe | 22                 | 17                     |

**Transplantations**

HLA-identical siblings were used for 38(30.2%) patients, matched unrelated donors for 66(52.4%), mismatched unrelated donors for 19(15.1%) and haploidentical related donors for 3(2.4%). There were 86(68.2%) patients, who received myeloablative conditioning (MAC), 35(27.8%) reduced-intensity conditioning (RIC), and 5(4%) non-myeloablative conditioning (NMA).

**Treatment after transplantation**

Thirty-four patients (27%) received additional therapy after transplantation (mainly azacitidine) aimed at preventing relapse. The detailed information on this treatment is provided in the Supplement.
**Immunosuppressive therapy**

All patients received prophylactic anti-GvHD treatment, including 84 patients (67%)-cyclosporine A(CsA) and 28(22%)-tacrolimus (TAC), together with short course of methotrexate. Other protocols included: CsA or TAC combined with mycophenolate mofetil (MMF) (4 patients(3%)) or TAC with sirolimus (6 patients(5%)). Three patients received either MMF (2 patients(2%)) or sirolimus (1 patient(1%)).

**GvHD**

Acute graft-versus-host disease (aGvHD) was diagnosed in 39 patients (30.9%) including 28(22.2%) with grade 1-2, and 11(8.7%) with grade 3-4. Chronic graft-versus-host disease (cGvHD) was diagnosed in 81 patients (64%), including 13(10%) with mild, 46(37%)-moderate, and 22(17%)-severe cGvHD.

**Prevalence of IgG deficiencies after allo-HSCT**

Hypogammaglobulinemia below 500mg/dL detected at least once occurred in 32.5% of patients (41 out of 126). In most patients, hypogammaglobulinemia was occasional and transient, and only in 10.3% of patients (13 out of 126), it was chronic. Additionally, in 25 patients IgG level below 700mg/dL but above 500mg/dL was observed making the total number of IgG deficient patients 66 out of 126(52.4%). 47% of patients did not have a decreased IgG level and about 4% of them had hypergammaglobulinemia. Eight patients developed monoclonal gammopathy. IgG deficiencies and the use of IgG supplementation are summarized in Table 2.

| IgG (mg/dL) | Number of patients (Share of the total) | Prophylactic IgG (Share of the total) | Therapeutic IgG (Share of the total) | Relapse (Share of the total) | Death (Share of the total) |
|-------------|----------------------------------------|---------------------------------------|-------------------------------------|----------------------------|----------------------------|
| < 200       | 1 (0.1%)                               | 1 (0.1%)                              | 0                                   | 0                          | 0                          |
| 200 - 300   | 8 (6.3%)                               | 4 (3.1%)                              | 4 (3.1%)                            | 1 (0.1%)                  | 1 (0.1%)                  |
| 300 - 400   | 13 (10.3%)                             | 10 (7.9%)                             | 3 (2.4%)                            | 3 (2.4%)                  | 3 (2.4%)                  |
| 400 - 500   | 19 (15%)                               | 10 (7.9%)                             | 9 (7%)                              | 4 (3.1%)                  | 5 (4.4%)                  |
| 500 - 700   | 25 (20%)                               | 0                                     | 12 (9.4%)                           | 3 (2.4%)                  | 4 (3.1%)                  |
| 700 - 1600  | 55 (44%)                               | 0                                     | 0                                   | 6 (4.9%)                  | 6 (4.9%)                  |
| > 1600      | 5 (4.3%)                               | 0                                     | 0                                   | 1 (0.1%)                  | 1 (0.1%)                  |
| Total       | 126 (100%)                             | 25 (19%)                              | 28 (22%)                            | 18 (13%)                  | 20 (15%)                  |

Altogether 53 out of 126 patients (42%) required IgG supplementation with exogenous immunoglobulin. Immunoglobulin facilitated subcutaneously by recombinant human hyaluronidase was used in 85%
cases and solution 165mg/mL- in 15% cases.

IgG was administered to all patients in whom IgG level was below 500mg/dL (41 patients (32.5%)). In 25 of them, it was only prophylactic, while in the remaining 16 also therapeutic because of recurrent infections. Additionally, 12 patients with IgG in the range 500-700mg/dL with accompanying severe and recurrent infections also received IgG supplementation. Therefore, the entire group of patients with infection receiving IgG supplementation comprised 28 patients (16 with IgG below 500mg/dL and 12 with IgG in the range 500-700mg/dL). The median number of IgG administrations was 3.5 (range 1-8) in the prophylactic, and 2 (range 1-8) in the group with infection.

The occurrence of the following invasive or life-threatening infections was used as an indication for IgG administration: fungal pneumonia- 7 patients (25%), bacterial pneumonia- 2(7%), sepsis within preceding months- 15(53%), recurrent local infection- 7(24%), viral infection- 25(89%)(including BK virus infection of the urinary tract- 10(35.7%), CMV reactivation- 10 (35.7%)) and polymicrobial infections- 13 patients(46%).

Beside IgG supplementation, they received appropriate routine antimycotic, antibacterial or/and antiviral treatment. Patients with BK virus infection did not receive any antiviral treatment.

The median time to the rst IgG administration was 4.1 months (range 1.1-74.2) after allo-HSCT, and 13 months after diagnosis (for the entire group)(range 4.1-173.9).

Median IgG levels before IgG therapy initiation was 460mg/dL (range 190-480) in the prophylaxis group, 446mg/dL (range 200-494) in patients with IgG level below 500mg/dL and recurrent infections and 557mg/dL (range 519-670) in the group of patients with infections and IgG level below 700 but above 500mg/dL.

Thirteen of 126(10.3%) patients (3 out of 3 with chronic lymphocytic leukemia (CLL), 1 out of 4 with Hodgkin lymphoma (HL), 6 out of 68 with AML and 3 out of 17 with ALL) required regular IgG supplementation throughout the follow-up period with median 8 administrations per year (range 8-9).

While it is a retrospective and not a prospective study aiming at assessing regular pharmacokinetics, patients were controlled for IgG concentration at various time points after IgG subcutaneous administration. Nevertheless, subcutaneous IgG significantly increased IgG concentration that was maintained for 6-8 weeks (Fig.1). Patients originally suffering from ALL(82%) and lymphoma(58%) most frequently met the criteria for IgG supplementation and were accordingly treated. The characteristics of patients treated with IgG are shown in Table S3 (supplement).

**Survival analysis**

The 1-year overall survival (1-y OS) was 97.1%(95% CI, 89.1-99.3), 95.8%(95% CI, 73.9-99.4), 80.6%(95% CI, 51-93.3), 63.5%(95% CI, 28.9-84.7) in the group that never required immunoglobulin supplementation, in the prophylactic IgG group, in the group with recurrent infections treated with IgG because of IgG level
below 500mg/dL, and finally, in the group treated with IgG because of recurrent infections and IgG 500-700mg/dL respectively. Relapse was the primary cause of death in 7 out of 7 patients, 4 out of 5 patients, 4 out of 4 patients and 3 out of 4 patients respectively.

The 1-y OS differences were not statistically significant with one exception; in the group with recurrent infections treated with IgG because of IgG level within 500-700mg/dL 1-y OS was significantly lower compared to the group never required immunoglobulin supplementation (p=0.009). The survival curves for all groups using Kaplan-Meier estimator are presented in Fig.2. Detailed results of the statistically significant 1-y OS differences for all groups are shown in Table S5.

Despite the fact that relapse contributed to death of 90% of all deceased patients, various infections complicated the course of relapse (mainly pneumonia or sepsis). Nine out of 10 patients (90%) with BKV infection receiving IgG improved, and thus achieved successful control of hemorrhagic cystitis, while 1 patient died (10%) due to relapse of the underlying disease. Detailed causes of death and diagnosed infections that occurred during the last 14 days of patients' lives are presented in Table S4.

**Factors predictive for IgG supportive treatment**

In the logistic regression model, the diagnosis of ALL or CLL and the use of systemic corticosteroid therapy were associated with the need for IgG supplementation. The average probability that a patient diagnosed with ALL or CLL will require IgG supplementation was 83.8%, while for patients with other diagnoses the average probability was 39.3% (p=0.0001). The use of corticosteroids was associated with the average probability of hypogammaglobulinemia requiring IgG supplementation in 64.2%, while no corticosteroid use with 31.5% (p=0.005) only.

**Toxicity**

Adverse events were observed in 53% patients treated with fscIgG, including 49%- grade 1 and 4%- grade 2. In two male patients (5%) transient scrotal oedema was observed, which resolved without any medical intervention. Malaise was reported in 2 patients (4%) and discomfort at the injection site in 10 patients (22%) patients. In 6 patients (13%) who suffered from chronic kidney disease- a clinically insignificant transient decrease in creatinine clearance was observed. In 3 patients (6%) of all treated patients, the change of the type of IgG products was required due to an allergic skin reaction at the application site.

**Discussion**

Apart from relapse of the underlying malignancy, secondary immunodeficiency is the most common complication of allo-HSCT. All patients are affected to some degree. It results in the occurrence of infectious complications, but also in an increased risk of relapse by altered effectiveness of graft-versus-leukemia reaction [3-6,17]. The occurrence of immunodeficiency, due to the altered and insufficient recovery of the immune system, is influenced by many factors including pre-transplant, like patient's age, type of the underlying medical condition and its treatment (including a growing number of therapeutics
targeting B cells), peri-transplant factors related to the transplantation procedure, e.g. the type of the donor, type of conditioning, ATG use and post-transplant factors i.e. multi-stage course of reconstitution, complications especially GvHD, immunosuppressive treatment and preventive treatment used after transplantation [18-22].

While this immunodeficiency is complex involving various parts and mechanisms of the immune system with limited possibility for intervention, the deficiency of immunoglobulins, particularly IgG can be corrected with exogenous preparations. Nevertheless expert opinions regarding IgG supplementation after allo-HSCT remain ambiguous [23-27].

In our group allo-HSCT recipients, IgG deficiency was usually transient and the supplementation of IgG was interventional in most cases. Approximately 32% of recipients required incidental IgG supplementation while 10%- regular. Patients received immunoglobulins when they met the predefined criteria i.e. when either the IgG level was below 500mg/dL, or below 700mg/dL (but above 500mg/dL) with frequent infections or both.

The IgG level used in this study as the indication for preventive IgG supplementation was higher than the one (<400mg/dL) recommended by the ASBMT (American Society for Blood and Marrow Transplantation) and EBMT (The European Society for Blood and Marrow Transplantation) guidelines [6,8]. The reason for this modification was the use of subcutaneous preparation of IgG, which efficacy in this population of patients was unknown.

Given possible qualitative and functional shortages of immunoglobulins, we used IgG replacement as well in patients with higher IgG concentration as support therapy in infections. It is hard to assess the effectiveness of IgG reliably because we administered causal treatment, usually at the same time. Nevertheless, it should be emphasized, that IgG supplementation was very effective in the treatment of symptomatic BK Polyomavirus- associated hemorrhagic cystitis (grade II or III according to the ECIL-6 Guidelines) [28,29]- 90% of those patients achieved resolution of symptoms without any antiviral treatment.

The median time to the first IgG administration (4.1 months) in our analysis appears to be consistent with the course of B-cell reconstitution, described in the literature [4,5]. Most of supplemented patients suffered from GvHD. Both acute and chronic GvHD are associated with delayed B cell reconstitution, reduction or lack of B cell precursors in the bone marrow and delays in IgG2 and IgG4 production [5,30,31]. Whether IgG supplementation may be useful to correct deficiencies of different IgG subclasses was beyond the scope of this study.

Cordonnier et al reported an increased risk of fatal veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients with acute GvHD receiving IgG replacement [32]. In our work, the shortest time to first administration was 34 days and we did not observe this complication.
Survival analysis revealed inferior survival in the group with infections than the prophylactic group but the vast majority of patients who eventually died, succumbed primarily to relapse of their leukemia with infection being only an accompanying condition. It needs another studies to confirm that such groups of patients with lower levels of IgG relapses most often than patients without IgG immunodeficiency.

In our study, the occurrence of IgG deficiency was found to be mainly dependent on the disease being an indication for transplantation, with ALL and CLL being the most common, and on systemic use of corticosteroid throughout the treatment process. In patients with B-cell malignancies total and/or functional hypogammaglobulinemia results from disease-related effects on the immune system and from side effects of the treatment [19,26,27]. Anti-B-cell therapy used before transplantation may be responsible for the development of post-transplantation complications. Low pre-allo-HSCT IgG level is a significant risk factor for hypogammaglobulinemia after transplantation [18-21].

In our study, no correlation for IgG replacement was found for GvHD (acute and/or chronic). The results of our analysis may be due to small number of analyzed patients, but also may indicate a stronger impact of steroid therapy than the diagnosis of GvHD on the occurrence of hypogammaglobulinemia. Corticosteroids are the current gold-standard for the treatment of GvHD [6]. According to published studies [5,31] it is difficult to determine the causality of antibody deficiency following allo-HSCT in a situation where both GvHD and the corticosteroid therapy can lead to antibody deficiency. Greinix et al. described that impairment of reconstitution, observed in patients with GvHD (either acute or chronic) cannot be separated from the possible influence of corticosteroids [33].

To our best knowledge, this study is the first to describe the effectiveness and safety of subcutaneous preparations instead of intravenous. This treatment was well tolerated, and we did not observe any significant toxicity. According to the literature, IgG has a half-life of about 21 to 29 days following intravenous administration [34]. However, especially in patients with immunodeficiencies, interindividual variation has been reported. Taking into consideration variability of the patient's situation (different time after transplantation, different initial diagnosis, the severity of GVHD) and also the fact that they had endogenous IgG production (albeit reduced) these data have shown that subcutaneous IgG significantly increased IgG level that was maintained for 6-8 weeks.

While there was no systematic pharmacokinetic experiment, our data collected from patients more frequently tested may unexpectedly suggest that the half-life of subcutaneously administered IgG is longer than intravenously, at least in this setting, in which some endogenous IgG production is present [34-36]. This would require verification in a prospective study but is interesting and potentially useful. Promising results of the scIgG treatment may grant a possibility of at-home treatment for selected patients after allo-HSCT.

To conclude, over 40% of the adult stem cell recipients may require immunoglobulin supplementation. A vulnerable group of patients to the development of hypogammaglobulinemia after allo-HSCT are patients with B-cell neoplasms, such as acute lymphoblastic leukemia or chronic lymphocytic leukemia, as well as...
patients treated with corticosteroids after transplantation. Subcutaneous immunoglobulins replacement seems to be a safe and efficacious alternative to intravenous IgG preparations in patients after allo-HSCT.

Declarations

Funding

The authors did not receive support from any organization for the submitted work.

Conflicts of interest

**Financial interests:** Author Wiesław Wiktor Jędrzejczak has received research support from: Roche, Novartis, Celgene, Janssen-Cilag, Takeda, Abbvie and BMS companies.

Other Authors declare no financial interests.

Availability of data and material

All patient data was collected based on available medical records. All of the data was analyzed anonymously.

Code availability

Not applicable.

Authors’ contribution

All authors contributed to the study conception. The first draft of the manuscript was written by Ewa Karakulska-Prystupiuk and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. All contribution data was attached to the title page.

Ethics approval

The ethical consent was approved by Medical University of Warsaw, Bioethical Commission.

Consent to participate

This is a retrospective analysis of anonymous data contained in medical records.

Consent for publication

Not applicable because there is no identifying information about patients.

Acknowledgements
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

We thank all the patients, their families and the members of staff involved in their care.

References

1. Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, Dolstra H, Lenkester AC, Mohty M, Montoto S, de Latour RP, Snowden JA, Styczyński J, Yakoub-Agha I, Kröger N. European Society for Blood and Marrow Transplantation (EBMT). The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplant. 2020 Aug;55(8):1604-1613.

2. Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Lyungman P, Averbuch D, de la Camara R, Baldomelo H, Bader P, Basak G, Bonini C, Duarte R, Dufour C, Kuball J, Lankester A, Montoto S, Nagler A, Snowden JA, Kröger N, Mohty M, Gratwohl A. Infectious Diseases Working Party EBMT. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 2020 Jan;55(1):126-136.

3. Norlin AC, Saira D, Mattsson J, Ljungman P, Ringdén O, Remberger M. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant. 2008 Feb;41(3):267-73.

4. Storek J. Immunological reconstitution after hematopoietic cell transplantation - its relation to the contents of the graft. Expert Opin Biol Ther. 2008 May;8(5):583-97.

5. Ogonek J, KraljJuric M, Ghimire S, Varanasi PR, Holler E, Greinix H, Weissinger E. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2016 Nov 17;7:507.

6. Carreras E, Dufour C, Mohty M, Kroger N (eds), The EBMT Handbook 2019, eBook, https://doi.org/10.1007/978-3-030-02278-5.

7. Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marr KA, Montoya JG, Morris-Engemann A, Pappas PG, Rolston K, Segal B, Seo SK, Swaminathan S, Naganuma M, Shead DA. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1412-45.

8. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ. Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious
complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238.

9. Edgar JDM, Richter AG, Huissoon AP, Kumararatne DS, Baxendale HE, Bethune CA, Garcez T, Misbah SA, Sorensen RU. United Kingdom Primary Immunodeficiency Network (UKPIN) Immunoglobulin Decision to Treat Study Group. Prescribing Immunoglobulin Replacement Therapy for Patients with Non-classical and Secondary Antibody Deficiency: an Analysis of the Practice of Clinical Immunologists in the UK and Republic of Ireland. J Clin Immunol. 2018 Feb;38(2):204-213.

10. Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W, Mousset S, Neuberger S, Neumann S, Penack O, Silling G, Vehreschild JJ, Einsele H, Maschmeyer G. Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation). Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016 Sep;95(9):1435-55.

11. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD006501.

12. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1.

13. Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, Wölfli M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhtovtsova Z, Ferrara JL, Levine JE. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016 Jan;22(1):4-10.

14. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974; 18(4):295-304.

15. Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, de Lavallade H, Gallo G, Lehrnbecher T, Engelhard D, Ljungman P. on behalf of the European Conference on Infections in Leukaemia group, Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet Infect Dis 2019; 19 (6), E200-E212.

16. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 e-pub: https://ctep.cancer.gov.
17. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner D, Meyers JD, Counts GW, Bowden RA, Peterson FB, Witherspoon RP. Immunomodulatory and Antimicrobial Efficacy of Intravenous Immunoglobulin in Bone Marrow Transplantation. N Engl J Med 1990; 323:705-712.

18. Arai Y, Yamashita K, Mizugishi K, Kondo T, Kitano T, Hishizawa M, Kadowaki N, Takaori-Kondo A. Risk factors for hypogammaglobulinemia after allo-SCT. Bone Marrow Transplant. 2014;49:859-861.

19. Frangoul H, Min E, Wang W, Chandrasekhar R, Calder C, Evans M, Manes B, Bruce K, Brown V, Ho R, Domm J. Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT. Bone Marrow Transplant. 2013;48:1456-1459.

20. De Angelis F, Tosti ME, Capria S, Russo E, D’Elia GM, Annechini G, Stefanizzi C, Foà R, Pulsoni A. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study. Leuk Res. 2015 Dec;39(12):1382-8.

21. Forcina A, Rancoita PMV, Marcatti M, Greco R, Lupo-Stanghellini MT, Carrabba M, Marasco V, Di Serio C, Bernardi M, Peccatori J, Corti C, Bondanza A, Ciceri F. A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Dec;23(12):2151-2158.

22. Patel SY, Carbone J, Jolles S. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. Front Immunol. 2019 Feb 8;10:33.

23. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, Nelson R, Secord E, Jordan SC, Stiehm ER, Vo AA, Ballow M. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017 Mar;139(3S):S1-S46.

24. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C. Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006 Apr;117(4 Suppl):S525-53.

25. Ueda M, Berger M, Gale RP, Lazarus HM. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Rev. 2018 Mar;32(2):106-115.

26. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Mey U. ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v78-84.

27. Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017 Jun;188(3):333-341.

28. Cesaro S, Dalianis T, Hanssen-Rinaldo C, Koskenvuo M, Pegoraro A, Einsele H, Cordonnier C, Hirsch HH. ECIL-6 Group. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018 Jan 1;73(1):12-21.
29. Sawinski D, Goral S. BK virus infection: an update on diagnosis and treatment. Nephrol Dial Transplant. 2015 Feb;30(2):209-17.

30. Reis M, Ogonek J, Qesari M, Borges NM, Nicholson L, Preußner L, Dickinson AM, Wang XN, Weissinger EM, Richter A. Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications. Front Immunol. 2016 Nov 14;7:500.

31. D’Costa S, Slobod KS, Benaim E, Bowman L, Cunningham J, Holladay M, Howlett N, Srivastava DK, Hurwitz JL. Effect of extended immunosuppressive drug treatment on B cell vs T cell reconstitution in pediatric bone marrow transplant recipients. Bone Marrow Transplant. 2001 Sep;28(6):573-80.

32. Cordonnier C, Chevret S, Legrand M, Rafi H, Dhédin N, Lehmann B, Bassompierre F, Gluckman E. GREFIG Study Group. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med. 2003 Jul 1;139(1):8-18.

33. Greinix HT, Pohlreich D, Kouba M, Körmöczi U, Lohmann I, Feldmann K, Zielinski C, Pickl WF. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008 Feb;14(2):208-19.

34. DeRienzo SY, Chiang KY, O’Neal WM, Godder K, Abhyankar S, Christiansen NP, Bridges KD, Henslee-Downey PJ. Evaluation of the half-life of intravenous human cytomegalovirus immune globulin in patients receiving partially mismatched related donor bone marrow transplantation. Pharmacotherapy. 2000 Oct;20(10):1175-8.

35. Dimou M, Iliakis T, Maltezas D, Bitsani A, Kalyva S, Koudouna A, Kotsanti S, Petsa P, Papaioannou P, Kyrtonis MC, Panayiotidis P. Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis. Anticancer Res. 2018 Jul;38(7):4187-4191.

36. Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, Leibl H, McCoy B, Empson VG, Gelmont D, Schiff RI. IGSC, 10% with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012 Oct;130(4):951-7.e11.

Figures
Figure 1

Change in IgG concentration after supplementation over time in 8 evaluated patients

Figure 2

Overall survival of patients with and without IgG supplementation
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- supplement.docx